Tesorai raises $5.3M to make raw lab data searchable for AI research
What's the deal? TesoraiDealroom has a profile for this one. Try Dealroom →, a San Diego AI startup building tools for life sciences research, has raised $5.3 million in seed funding. The round was led by Perplexity FundDealroom has a profile for this one. Try Dealroom →, IQT, and South Central VenturesDealroom has a profile for this one. Try Dealroom →, with New Stack VenturesDealroom has a profile for this one. Try Dealroom →, NextGen Venture PartnersDealroom has a profile for this one. Try Dealroom →, f7 VenturesDealroom has a profile for this one. Try Dealroom →, VitalStage VenturesDealroom has a profile for this one. Try Dealroom →, and ZAKADealroom has a profile for this one. Try Dealroom → participating. It brings Tesorai's total funding to $8 million.
What's the endgame? Tesorai analyzes raw experimental data from both new and published studies, standardizing results so researchers can search and compare them. The aim is to surface findings overlooked in earlier analyses, rather than relying on summarized published results.
Why now? AI-driven drug discovery remains starved of usable data, even as labs generate terabytes daily. Tesorai's platform has processed thousands of files within hours — work that previously took months — according to the company.
What's the proof? In August 2026, Tesorai reprocessed raw data from five published brain studies and identified p-tau217, an Alzheimer's biomarker not reported in the originals. The findings were published as a preprint and have not undergone peer review.
The startup plans to use the money to expand work with biopharmaceutical companies, add partnerships with life sciences technology providers, and extend its platform beyond protein analysis to other molecular data.
"Every experiment produces far more data than its paper can report, and most of it is never revisited," said Melissa Miao, co-founder and chief executive officer. "Our platform reclaims the value of experiments that have already been done."
The signal: Tesorai's raise is a bet on a bottleneck in AI research: not generating more biological data, but using what exists. While rivals like Isomorphic Labs raise billions to design drugs, Tesorai sells data-access infrastructure — and its payoff hinges on sustained adoption and proof that recovered insights improve outcomes.
Read more: citybiz.co
Image credit: "Sample Analysis at Mars (SAM) Media Day" by NASA Goddard Photo and Video, licensed under CC BY 2.0